Becton Dickinson and Co (NYSE:BDX) – Equities researchers at Leerink Swann reduced their FY2019 earnings per share estimates for shares of Becton Dickinson and in a note issued to investors on Wednesday, November 7th. Leerink Swann analyst R. Newitter now expects that the medical instruments supplier will post earnings of $12.09 per share for the year, down from their previous forecast of $12.61. Leerink Swann also issued estimates for Becton Dickinson and’s FY2020 earnings at $13.70 EPS.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $2.93. The company had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.40 EPS.

Several other equities research analysts have also commented on BDX. Piper Jaffray Companies decreased their price target on Becton Dickinson and to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday. Barclays set a $260.00 price target on Becton Dickinson and and gave the stock a “hold” rating in a research note on Thursday. Wells Fargo & Co decreased their price target on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday. KeyCorp boosted their price target on Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Citigroup boosted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $254.07.

Shares of NYSE:BDX opened at $243.26 on Thursday. The company has a market cap of $63.38 billion, a PE ratio of 22.09, a PEG ratio of 1.46 and a beta of 1.19. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and has a 12 month low of $209.91 and a 12 month high of $265.87.

In related news, EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total value of $1,257,606.04. Following the sale, the executive vice president now owns 13,318 shares of the company’s stock, valued at approximately $3,227,750.48. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BDX. Fundsmith Equity Fund L.P. acquired a new position in Becton Dickinson and in the 2nd quarter valued at $894,775,000. FMR LLC raised its holdings in Becton Dickinson and by 13.7% in the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock valued at $4,069,559,000 after acquiring an additional 2,049,874 shares during the last quarter. Charles Schwab Investment Advisory Inc. acquired a new position in Becton Dickinson and in the 2nd quarter valued at $291,167,000. Vontobel Asset Management Inc. raised its holdings in Becton Dickinson and by 823.0% in the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock valued at $250,205,000 after acquiring an additional 904,097 shares during the last quarter. Finally, Cornerstone Wealth Management LLC raised its holdings in Becton Dickinson and by 233.6% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock valued at $3,286,000 after acquiring an additional 453,623 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Recommended Story: Outstanding Shares and The Effect on Share Price

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.